Scarica l'app Stockscreener
4.81
9.07%
-0.48
Dopo l'orario di chiusura:
4.85
0.04
+0.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$5.29
Aprire:
$4.91
Volume 24 ore:
18.20M
Relative Volume:
0.83
Capitalizzazione di mercato:
$1.93B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-3.1032
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
-19.43%
1M Prestazione:
-27.01%
6M Prestazione:
-20.63%
1 anno Prestazione:
-46.14%
Intervallo 1D:
$4.78
$5.03
Intervallo di 1 settimana:
$4.78
$6.005
Portata 52W:
$4.78
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.81 | 1.93B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March - Yahoo Finance
Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market - Yahoo Finance
Recursion to Participate in Upcoming Investor Conference - Bluefield Daily Telegraph
Recursion stock hits 52-week low at $5.5 amid market challenges - Investing.com Canada
Recursion stock hits 52-week low at $5.5 amid market challenges By Investing.com - Investing.com South Africa
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today - Yahoo Finance
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? - Yahoo Finance
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks - The Motley Fool
Recursion Pharmaceuticals CEO sells $836,986 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals CEO sells $836,986 in stock - Investing.com India
Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday? - MSN
Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts (NASDAQ:RXRX) - Seeking Alpha
(RXRX) Investment Report - Stock Traders Daily
Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit? - Insider Monkey
12 Best AI Stocks to Invest in According to Reddit - Insider Monkey
Why Recursion Pharmaceuticals (RXRX) Went Up on Monday? - MSN
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
RXRX Quantitative Stock AnalysisBenjamin Graham - Nasdaq
Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering - Yahoo Finance
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock? - Zacks Investment Research
Recursion Pharmaceuticals Strengthens Board with New Appointments - TipRanks
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun - Yahoo Finance
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Recursion Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
Jones Financial Companies Lllp Has $229,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer - Business Wire
Proficio Capital Partners LLC Makes New $163,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns - Seeking Alpha
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’ - Insider Monkey
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip - MSN
Why Recursion Pharmaceuticals Stock Is Sinking Today - Yahoo Finance
Jim Cramer’s Latest Lightning Round: 8 Stocks in Focus - Insider Monkey
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? - Nasdaq
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip - Benzinga
QRG Capital Management Inc. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
This Is What Whales Are Betting On Recursion Pharmaceuticals - Benzinga
Private Advisor Group LLC Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today - MSN
This Biotech Stock Could Be the Best Investment of the Decade - The Globe and Mail
April 25th Options Now Available For Recursion Pharmaceuticals (RXRX) - Nasdaq
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? - MSN
IFP Advisors Inc Acquires 7,455 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):